In this installment of “Just a Phase,” we look at the phase 2a LIFT trial of TERN-101 (Terns Pharmaceuticals) for the treatment of patients with nonalcoholic steatohepatitis (NASH). The results suggest the drug can lead to improvement in key noninvasive tests associated with NASH severity, and it has an attractive safety profile with no discontinuations due to side effects.
TERN-101 is a liver-distributed farnesoid X receptor (FXR) agonist. The LIFT study was a multicenter,